Transaction #9502 · Form 4 · 0001213900-25-112277
Vyome Holdings, Inc · Stock award · Common Stock
Vyome Holdings, Inc · Transacted August 15, 2025 · Filed November 18, 2025
What does this filing report?
An SEC Form 4 filing for Vyome Holdings, Inc records a stock award involving Common Stock on August 15, 2025. The reported quantity was 454,456. The filing date is November 18, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Vyome Holdings, Inc
- Company CIK
- 0001427570
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 454,456
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 454,456
- Ownership description
- See footnote
- SEC acceptance time
- Nov 18, 2025, 6:45 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Jolly Mohanjit ↗
Director
CIK 0001867575
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.
- F2
- Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.